Michael Peroski, DO
Psychiatry · Dubuque, IANPI 1689092454
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $594, 7.1 times the $84 reported in 2019.
Across 119 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$364
- Teva Pharmaceuticals USA, Inc.$246
- Otsuka America Pharmaceutical, Inc.$178
- Axsome Therapeutics, Inc.$174
- Alkermes, Inc.$161
- Corium, LLC$152
- plus $742 from 14 others
What the payments were for
- Food & beverage$1,97098%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $364 |
| Teva Pharmaceuticals USA, Inc. | 14 | $246 |
| Otsuka America Pharmaceutical, Inc. | 10 | $178 |
| Axsome Therapeutics, Inc. | 9 | $174 |
| Alkermes, Inc. | 9 | $161 |
| Corium, LLC | 9 | $152 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $148 |
| Johnson & Johnson | 8 | $106 |
| Livanova USA, Inc. | 4 | $106 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Neurocrine Biosciences, Inc. | 4 | $62 |
| Acadia Pharmaceuticals Inc | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Indivior Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Harmony Biosciences LLC | 3 | $27 |
| Lilly USA, LLC | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $11 |
How this compares
$2,017 in reported general payments places this provider in the 85th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 39 | $310,667 |
| AustedoDeutetrabenazine | 50 | $187,792 |
| TrintellixVortioxetine Hydrobromide | 108 | $62,742 |
| RexultiBrexpiprazole | 41 | $55,014 |
| CaplytaLumateperone Tosylate | 39 | $51,472 |
| FanaptIloperidone | 15 | $50,956 |
| NuplazidPimavanserin Tartrate | 19 | $47,226 |
| VraylarCariprazine Hcl | 32 | $45,456 |
| Clozapine | 278 | $20,265 |
| FetzimaLevomilnacipran Hcl | 62 | $17,439 |
| BelsomraSuvorexant | 38 | $16,416 |
| Duloxetine Hcl | 588 | $16,065 |
| Paliperidone ErPaliperidone | 58 | $15,533 |
| Aripiprazole | 175 | $13,536 |
| Vilazodone Hcl | 122 | $12,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $62 | $310,66739 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $246 | $187,79250 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $29 | $70,172120 claims |
| AbbVieVraylar, Fetzima | $364 | $62,89594 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $178 | $55,01441 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $148 | $51,47239 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $32 | $50,95615 claims |
| Acadia Pharmaceuticals IncNuplazid | $52 | $47,22619 claims |
| Lilly USA, LLCOlanzapine | $22 | $3,775134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Dubuque
- Lee BermanDubuque$3K
- Anupama UpadhyayDubuque$1K
- Adib KassasDubuque$1K
- Peter SzeibelDubuque$891
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
- Alan WhittersCedar Rapids$170K
- Donald BlackIowa City$19K
- William CoryellIowa City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.